Immunovant jumps after antibody treatment shows promise in study

Immunovant

26/09/2023 11:54

** Shares of Roivant-backed Immunovant  IMVT.O  rise 45% to
$29.66 premarket
    ** Shares of Roivant Sciences  ROIV.O  rise 17% to $11.97
premarket
    ** ROIV is the largest shareholder in IMVT, according to
LSEG data
    ** IMVT says its experimental antibody drug showed reduction
in levels of IgG antibodies that cause inflammation and disease
    ** The drug candidate, IMVT-1402, was tested in healthy
adults as an under-the-skin injection, co says
    ** IMVT-1402 has potency similar to or greater than that of
batoclimab, co's drug being developed for autoimmune diseases
such as myasthenia gravis and Graves’ disease - IMVT
    ** Up to last close, IMVT shares up ~14% YTD; ROIV up ~28%
YTD  

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))